The risk of arterial embolism is well recognised following Direct Current Cardioversion (DCC) for atrial fibrillation although the use of prophylactic anticoagulation remains controversial. Aim: To determine the risk of arterial embolism post-cardioversion and which factors predict successful cardioversion and maintenance of sinus rhythm. Materials and Methods: A retrospective study was carried out ofall cardioversions performed for atrial fibrillation and atrial flutter at the Waveney Hospital Ballymena, during 1989-1993. A review of medical records and electrocardiograms was carried out to assess demographic characteristics, co-existent diseases, anticoagulant status, echocardiographic features and characteristics of the arrhythmia. Embolic events in the six weeks post-cardioversion were noted. Results: The study included 157 cardioversions in 109 patients. The predominant arrhythmia was atrial fibrillation (n=108, 69%). Three of 109 patients (2.7%) experienced embolic complications, none of whom had anticoagulation prior to the procedure. No risk factors for cerebro-vascular disease or significant valvular heart disease were present. Return to sinus rhythm was achieved in 143 (91 %) procedures. Increasing coarseness of atrial fibrillation was associated with a non-significant trend towards successful restoration of sinus rhythm (p=O.l 8). Recurrence of the original arrhythmia was predicted by an increase in coarseness of atrial fibrillation (p<O.O5). Conclusions: These findings indicate that embolic complications can occur in patients undergoing DCC with normal echocardiographic dimensions, and that prophylactic anticoagulation should be considered in all patients. Coarseness of atrial fibrillation may be used as a guide to predict the chance of successful cardioversion and of the likelihood of maintaining sinus rhythm once this has been achieved.
INTRODUCTION
Atrial fibrillation is the commonest sustained arrhythmia. Chronic atrial fibrillation is associated with a doubling of mortality,' largely due to an increase in the incidence of stroke. 2 The potential benefits of a return to sinus rhythm are a reduction in the risk of systemic embolisation and an improvement in haemodynamics secondary to the return of atrial mechanical function. 3 Return to sinus rhythm may occur spontaneously or may be achieved by chemical or electrical cardioversion. Direct Current Cardioversion (DCC) in atrial fibrillation is a successful, safe procedure and should be considered for all patients regardless of aetiology. DCC is known to be highly effective for the immediate conversion of atrial fibrillation to sinus rhythm. 4 The risk of embolism following DCC for atrial fibrillation is well recognised but the use ofroutine prophylactic anticoagulation remains somewhat controversial. Certain factors, such as duration of atrial fibrillation, left atrial size as assessed by Mmode echocardiography and aetiological associations may be predictive of a successful restoration of sinus rhythm, although these have not been confirmed by Dittrich.s We reviewed the results of 202 cardioversions for atrial fibrillation and atrial flutter over a five year period to assess further the need for prophylactic anticoagulation. In addition, we have attempted to determine factors predicting the risk ofthrombo-embolism post-cardioversion and also those parameters predicting successful cardioversion and maintenance of sinus rhythm once this had been achieved.
MATERIALS AND METHODS
Between 1st January 1989 and 31st December 1993, 202 elective DCC procedures were undertaken in 116 adult patients (82 male) with atrial fibrillation or atrial flutter as the primary arrhythmia. Cardioversions in which atrial fibrillation or atrial flutter were present for less than 48 hours and cardioversions in which anticoagulant status was indeterminate were excluded from subsequent analysis. All cardioversions were carried out in the Coronary Care Unit under intravenous sedation with midazolam (usual dose 5-10 mgs). A series of synchronised direct current shocks ofincreasing energy was delivered starting with 50 Joules, and increasing incrementally until sinus rhythm was achieved or 360 Joules was reached. Pre-and post-cardioversion 12-lead electrocardiograms were available to verify heart rhythm. The medical records were reviewed for demographic characteristics and coexistent diseases (ischaemic heart disease, valvular heart disease, hypertension, diabetes mellitus or cerebro-vascular disease). Electrocardiographs were examined to confirm heart rhythm prior to DCC and to determine the duration of the arrhythmia. In patients with atrial fibrillation the "coarseness" of atrial electrical activity was assessed subjectively and determined to be "coarse", "intermediate" or "fine", depending on the baseline atrial electrical activity and mean "f' wave cycle length. In addition, left atrial size, left ventricular end-diastolic diameter and the presence or absence of valvular heart disease were noted in those patients in whom echocardiography had been performed. Ischaemic heart disease was the aetiological factor in 13 of 75 cardioversions which were followed by a recurrence of the original rhythm, compared to 23 of 68 cardioversions in which sinus rhythm was maintained (p<O.O1). Although a higher number of patients with mitral valve disease, hypertension and unknown aetiology experienced a recurrence of the original rhythm, these differences did not reach a significant level. The age of the patient and the duration of the arrhythmia were not predictive of relapse. The effect of anti-arrhythmic agents on relapse rates was not examined.
DISCUSSION
Synchronised electrical cardioversion for atrial fibrillation and atrial flutter may be complicated by systemic embolisation. This has been estimated to occur in up to 7% of patients. 6 The atrial arrhythmia most likely to be associated with embolic events is atrial fibrillation,7' 8 although one ofthree patients developing cerebral thromboembolism in our study had been cardioverted for atrial flutter.
Although it has been suggested that patients with atrial fibrillation should receive anticoagulation prior to undergoing direct current cardioversion,4 8 there has been a lack of consensus on such treatment prior to the period included in this study. Recently it has been recommended that anticoagulation should be given for three weeks before and four weeks after DCC for atrial fibrillation of more than 48 hours duration.9 Data is sparse on the incidence of embolism after cardioversion for specific arrhythmias. Lown 6 months which compares favourably with those ofDittrich5 who has reported rates of 69% and 58% at 1 and 6 months respectively. Useful and safe prophylaxis of atrial fibrillation has been demonstrated in selected groups of patients using anti-arrhythmic drugs from different classes, although a metanalysis of randomised control trials in the use of quinidine has indicated an increased total mortality.20 '2' Atrial fibrillation is a common arrhythmia that is associated with significant morbidity and mortality. Direct current cardioversion should be considered in all patients regardless of aetiology since initial success rates are high. Our findings indicate that embolic complications can occur in patients undergoing direct current cardioversion without prophylactic anticoagulation who have normal echocardiographic findings and no risk factors for cerebrovascular events. We therefore recommend that prophylactic anticoagulation should be considered in all patients with atrial fibrillation or atrial flutter of >1 week's duration prior to attempted cardioversion. Anticoagulation should be given for 4 weeks prior to and, at least, 4 weeks following elective cardioversion. Coarseness of atrial fibrillation may be used as a subjective guide to predicting the probability of achieving and maintaining sinus rhythm. The high relapse rates following successful cardioversion remain problematic and the role of prophylactic anti-arrhythmic drugs and nonpharmacological measures remains to be established in these patients with recurrent atrial arrhythmias.
